Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Imran Khan A. N"'
Autor:
Khader Shameer, Youyi Zhang, Andrzej Prokop, Sreenath Nampally, Imran Khan A. N, Jim Weatherall, Renee Bailey Iacona, Faisal M. Khan
Publikováno v:
JCO Clinical Cancer Informatics.
PURPOSE Overall survival (OS) is the gold standard end point for establishing clinical benefits in phase III oncology trials. However, these trials are associated with low success rates, largely driven by failure to meet the primary end point. Surrog
Autor:
Khader Shameer, Youyi Zhang, Dan Jackson, Kirsty Rhodes, Imran Khan A. Neelufer, Sreenath Nampally, Andrzej Prokop, Emmette Hutchison, Jiabu Ye, Vladislav A. Malkov, Feng Liu, Antony Sabin, Jim Weatherall, Cristina Duran, Renee Bailey Iacona, Faisal M. Khan, Pralay Mukhopadhyay
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Early endpoints, such as progression-free survival (PFS), are increasingly used as surrogates for overall survival (OS) to accelerate approval of novel oncology agents. Compiling trial-level data from randomized controlled trials (RCTs) could help to
Externí odkaz:
https://doaj.org/article/84b729da2ab44fd6bcfdfede4b9ff618